Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs01:15

Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs

Bioequivalence experimental study designs play a pivotal role in testing the effectiveness of various treatments. Key among these are the repeated measures, cross-over, carry-over, and Latin square designs. In the repeated measures design, each subject receives all treatments, allowing for temporal comparisons. This type of design is useful in reducing variability but requires careful planning to avoid bias.The cross-over design, an economical method, involves sequential administration of...
Bioequivalence: Overview01:16

Bioequivalence: Overview

Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and Cox...
Hazard Ratio01:12

Hazard Ratio

The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial evaluating a...
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Developing and Piloting an Instrument to Prioritize the Worries of Female Youth with a Physical Disability and Mothers during the Transition to Adulthood.

MDM policy & practice·2026
Same author

Factors Influencing Physician Adherence to Venous Thromboembolism Risk Assessment Model Recommendations: A Best-Worst Scaling.

American journal of cardiovascular drugs : drugs, devices, and other interventions·2026
Same author

Developing a Novel Values Elicitation Measure for Clinical Use in Older Adults with Hematologic Malignancies: Values-HM.

MDM policy & practice·2026
Same author

The concerns of mothers of female youth with physical disabilities in transitioning to adulthood: A qualitative study.

Journal of pediatric rehabilitation medicine·2026
Same author

Patient-reported outcomes for monitoring substance use treatment: A systematic review of single-item measures.

Addiction (Abingdon, England)·2026
Same author

How do US Adults Who Vape Choose Among Different E-Cigarette (EC) Models and Cigarettes in Response to Prices and Taxes.

Health economics·2026
Same journal

The Price of National Pharmaceutical Pricing in the EU: A Proposal for "Common Procurement".

Applied health economics and health policy·2026
Same journal

The Price of Speed: Estimating the Impact of List Prices on Time to Availability of New Medicines in 18 European Countries.

Applied health economics and health policy·2026
Same journal

Deprescribing Interventions in Older Adults with Polypharmacy: A Systematic Review of Economic Evaluations.

Applied health economics and health policy·2026
Same journal

Causal Impact of Primary Care and Publicly Funded Health Insurance on Catastrophic Health Spending From Climate-Sensitive Diseases in India.

Applied health economics and health policy·2026
Same journal

Health Economic Evaluations of Breast Cancer Screening Strategies: A Systematic Review Focusing on Methodology and Quality Assessment.

Applied health economics and health policy·2026
Same journal

Societal Preferences for Assessment Pathways of Rare Disease Drugs: A Discrete Choice Experiment.

Applied health economics and health policy·2026
See all related articles

Related Experiment Video

Updated: Jun 18, 2026

The Participant-Reported Implementation Update and Score (PRIUS): A Novel Method for Capturing Implementation-Related Data Over Time
06:05

The Participant-Reported Implementation Update and Score (PRIUS): A Novel Method for Capturing Implementation-Related Data Over Time

Published on: February 19, 2021

Assessing comparative effectiveness research in the US.

Joshua P Cohen1, John F P Bridges

  • 1Tufts University Center for the Study of Drug Development, Boston, Massachusetts 02111, USA. joshua.cohen@turfs.edu

Applied Health Economics and Health Policy
|November 13, 2009
PubMed
Summary
This summary is machine-generated.

Comparative effectiveness research (CER) is crucial for informing drug prescribing and reimbursement. A coordinated evidence base is needed to improve pharmaceutical care and close the gap between knowledge and practice.

More Related Videos

A Novel Method for Involving Women of Color at High Risk for Preterm Birth in Research Priority Setting
14:43

A Novel Method for Involving Women of Color at High Risk for Preterm Birth in Research Priority Setting

Published on: January 12, 2018

Related Experiment Videos

Last Updated: Jun 18, 2026

The Participant-Reported Implementation Update and Score (PRIUS): A Novel Method for Capturing Implementation-Related Data Over Time
06:05

The Participant-Reported Implementation Update and Score (PRIUS): A Novel Method for Capturing Implementation-Related Data Over Time

Published on: February 19, 2021

A Novel Method for Involving Women of Color at High Risk for Preterm Birth in Research Priority Setting
14:43

A Novel Method for Involving Women of Color at High Risk for Preterm Birth in Research Priority Setting

Published on: January 12, 2018

Area of Science:

  • Health Services Research
  • Pharmaceutical Policy
  • Evidence-Based Medicine

Background:

  • The US government's $1.1 billion investment in comparative effectiveness research (CER) signals its growing role in healthcare decisions.
  • Key questions arise regarding CER data nature, collection methods, responsibilities, and federal utilization.

Purpose of the Study:

  • To assess the current state of federally and state-funded CER in the US.
  • To analyze the implications of CER findings on prescribing and reimbursement decisions.
  • To propose improvements for a more systematic and coordinated evidence base.

Main Methods:

  • Analysis of three high-profile case studies involving drugs and drug classes.
  • Evaluation of federal and state-funded CER initiatives.
  • Review of evidence gathering and application in decision-making.

Main Results:

  • Evidence is increasingly used to filter prescribing and coverage decisions.
  • Post-hoc evidence gathering after reimbursement decisions is ineffective.
  • Systematic reviews have limitations when applied to individual patient treatment.
  • Comprehensive data gathering is costly and time-consuming.

Conclusions:

  • There is a need for a more systematic and coordinated evidence base in the US.
  • CER can help bridge the gap between pharmaceutical knowledge and practice.
  • A pluralistic system with a clearinghouse for systematic reviews is favored for CER analyses.